Recombinant DNA technology Market Size Report, 2023-2032
The global recombinant DNA technology market size was exhibited at USD 730.51 billion in 2022 and is projected to hit around USD 1202.46 billion by 2032, growing at a CAGR of 5.11% during the forecast period 2023 to 2032.
Key Pointers:
Recombinant DNA technology Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 767.84 Billion |
| Market Size by 2032 | USD 1202.46 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.11% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Component, Application, End User, Geography |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This has extended its usage in widespread applications including conventional as well as non-conventional applications. Over the past years, this space has witnessed tremendous achievement in the production of recombinant drugs and therapeutics without the help of human donors.
The classical example of this achievement is the commercial success of genetically engineered insulin for diabetes treatment. The biotech and pharmaceutical firms are engaged in deciphering the potential of rDNA techniques in various aspects of disease management. This is mainly to combat the soaring burden of chronic diseases and keep pace with the growing therapeutics demand.
Furthermore, the gradual evolution of rDNA techniques has drafted new vistas in taking biopharmaceutical development a step ahead by enabling the construction of a recombinant DNA molecule. The presence of a robust biopharmaceuticals pipeline, in particular, the recombinant proteins pipeline; is expected to drive the adoption of this technology. Development of recombinant products using rDNA techniques accompanied by CRISPR/Cas9 nuclease, ZFN, and TALEN for easy & precise genome editing with no limitation by organisms is largely responsible for the growth of this space. Dozens of review studies carried out by researchers are evident for the efficiency of rDNA technology.
Growth in Genetically Modified (GM) crop hectarage around the world is a testament to the success of this technology in the agriculture and food sector. This has triggered its usage in other non-conventional applications such as the development of biofuel and biopesticides to address environmental issues. However, the use of this technology has been a topic of controversies as a result of attendant ethical considerations in various applications such as gene therapy. In each of the diverse fields of medicine, agriculture, and the environment, scientific and ethical concerns vary in a discipline-specific manner.
Some of the prominent players in the Recombinant DNA technology Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global recombinant DNA technology market.
By Product
By Component
By Application
By End User
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Recombinant DNA Technology Market
5.1. COVID-19 Landscape: Recombinant DNA Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Recombinant DNA Technology Market, By Product
8.1. Recombinant DNA Technology Market, by Product, 2023-2032
8.1.1. Medical
8.1.1.1. Market Revenue and Forecast (2017-2032)
8.1.2. Non-Medical
8.1.2.1. Market Revenue and Forecast (2017-2032)
Chapter 9. Global Recombinant DNA Technology Market, By Component
9.1. Recombinant DNA Technology Market, by Component e, 2023-2032
9.1.1. Expression System
9.1.1.1. Market Revenue and Forecast (2017-2032)
9.1.2. Cloning Vector
9.1.2.1. Market Revenue and Forecast (2017-2032)
9.1.5.1. Market Revenue and Forecast (2017-2032)
Chapter 10. Global Recombinant DNA Technology Market, By Application
10.1. Recombinant DNA Technology Market, by Application, 2023-2032
10.1.1. Health and disease
10.1.1.1. Market Revenue and Forecast (2017-2032)
10.1.2. Food and Agriculture
10.1.2.1. Market Revenue and Forecast (2017-2032)
10.1.3. Environment
10.1.3.1. Market Revenue and Forecast (2017-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2032)
Chapter 11. Global Recombinant DNA Technology Market, By End User
11.1. Recombinant DNA Technology Market, by End User, 2023-2032
11.1.1. Pharmaceutical and biotechnology companies
11.1.1.1. Market Revenue and Forecast (2017-2032)
11.1.2. Research institutes
11.1.2.1. Market Revenue and Forecast (2017-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2017-2032)
Chapter 12. Global Recombinant DNA Technology Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2032)
12.1.2. Market Revenue and Forecast, by Component (2017-2032)
12.1.3. Market Revenue and Forecast, by Application (2017-2032)
12.1.4. Market Revenue and Forecast, by End User (2017-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2017-2032)
12.1.5.2. Market Revenue and Forecast, by Component (2017-2032)
12.1.5.3. Market Revenue and Forecast, by Application (2017-2032)
12.1.5.4. Market Revenue and Forecast, by End User (2017-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2017-2032)
12.1.6.2. Market Revenue and Forecast, by Component (2017-2032)
12.1.6.3. Market Revenue and Forecast, by Application (2017-2032)
12.1.6.4. Market Revenue and Forecast, by End User (2017-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2032)
12.2.2. Market Revenue and Forecast, by Component (2017-2032)
12.2.3. Market Revenue and Forecast, by Application (2017-2032)
12.2.4. Market Revenue and Forecast, by End User (2017-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2017-2032)
12.2.5.2. Market Revenue and Forecast, by Component (2017-2032)
12.2.5.3. Market Revenue and Forecast, by Application (2017-2032)
12.2.5.4. Market Revenue and Forecast, by End User (2017-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2017-2032)
12.2.6.2. Market Revenue and Forecast, by Component (2017-2032)
12.2.6.3. Market Revenue and Forecast, by Application (2017-2032)
12.2.6.4. Market Revenue and Forecast, by End User (2017-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2017-2032)
12.2.7.2. Market Revenue and Forecast, by Component (2017-2032)
12.2.7.3. Market Revenue and Forecast, by Application (2017-2032)
12.2.7.4. Market Revenue and Forecast, by End User (2017-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2017-2032)
12.2.8.2. Market Revenue and Forecast, by Component (2017-2032)
12.2.8.3. Market Revenue and Forecast, by Application (2017-2032)
12.2.8.4. Market Revenue and Forecast, by End User (2017-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2032)
12.3.2. Market Revenue and Forecast, by Component (2017-2032)
12.3.3. Market Revenue and Forecast, by Application (2017-2032)
12.3.4. Market Revenue and Forecast, by End User (2017-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2017-2032)
12.3.5.2. Market Revenue and Forecast, by Component (2017-2032)
12.3.5.3. Market Revenue and Forecast, by Application (2017-2032)
12.3.5.4. Market Revenue and Forecast, by End User (2017-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2017-2032)
12.3.6.2. Market Revenue and Forecast, by Component (2017-2032)
12.3.6.3. Market Revenue and Forecast, by Application (2017-2032)
12.3.6.4. Market Revenue and Forecast, by End User (2017-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2017-2032)
12.3.7.2. Market Revenue and Forecast, by Component (2017-2032)
12.3.7.3. Market Revenue and Forecast, by Application (2017-2032)
12.3.7.4. Market Revenue and Forecast, by End User (2017-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2017-2032)
12.3.8.2. Market Revenue and Forecast, by Component (2017-2032)
12.3.8.3. Market Revenue and Forecast, by Application (2017-2032)
12.3.8.4. Market Revenue and Forecast, by End User (2017-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2032)
12.4.2. Market Revenue and Forecast, by Component (2017-2032)
12.4.3. Market Revenue and Forecast, by Application (2017-2032)
12.4.4. Market Revenue and Forecast, by End User (2017-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2017-2032)
12.4.5.2. Market Revenue and Forecast, by Component (2017-2032)
12.4.5.3. Market Revenue and Forecast, by Application (2017-2032)
12.4.5.4. Market Revenue and Forecast, by End User (2017-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2017-2032)
12.4.6.2. Market Revenue and Forecast, by Component (2017-2032)
12.4.6.3. Market Revenue and Forecast, by Application (2017-2032)
12.4.6.4. Market Revenue and Forecast, by End User (2017-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2032)
12.4.7.2. Market Revenue and Forecast, by Component (2017-2032)
12.4.7.3. Market Revenue and Forecast, by Application (2017-2032)
12.4.7.4. Market Revenue and Forecast, by End User (2017-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2017-2032)
12.4.8.2. Market Revenue and Forecast, by Component (2017-2032)
12.4.8.3. Market Revenue and Forecast, by Application (2017-2032)
12.4.8.4. Market Revenue and Forecast, by End User (2017-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2032)
12.5.2. Market Revenue and Forecast, by Component (2017-2032)
12.5.3. Market Revenue and Forecast, by Application (2017-2032)
12.5.4. Market Revenue and Forecast, by End User (2017-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2017-2032)
12.5.5.2. Market Revenue and Forecast, by Component (2017-2032)
12.5.5.3. Market Revenue and Forecast, by Application (2017-2032)
12.5.5.4. Market Revenue and Forecast, by End User (2017-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2017-2032)
12.5.6.2. Market Revenue and Forecast, by Component (2017-2032)
12.5.6.3. Market Revenue and Forecast, by Application (2017-2032)
12.5.6.4. Market Revenue and Forecast, by End User (2017-2032)
Chapter 13. Company Profiles
13.1. Pfizer
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Sanofi
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. New England Biolabs
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GlaxoSmithKline plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GenScript
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Thermo Fisher Scientific, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Biogen, Inc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & Co., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Profacgen
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Amgen, Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers